Translate Bio, Inc. (TBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
TBIO Stock Price Chart Interactive Chart >
TBIO Price/Volume Stats
| Current price | $1.89 | 52-week high | $11.02 |
| Prev. close | $1.87 | 52-week low | $1.08 |
| Day low | $1.81 | Volume | 20,500 |
| Day high | $1.94 | Avg. volume | 69,906 |
| 50-day MA | $1.48 | Dividend yield | N/A |
| 200-day MA | $2.26 | Market Cap | 55.80M |
Translate Bio, Inc. (TBIO) Company Bio
Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts.
Latest TBIO News From Around the Web
Below are the latest news stories about Translate Bio Inc that investors may wish to consider to help them evaluate TBIO as an investment opportunity.
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)LEXINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees. These grants were made pursuant to the Company’s 2021 Indu |
'It's game over. It's mRNA or nothing:' Expert on future of vaccinesmRNA technology has taken the world by storm thanks to the success of two vaccine companies in 2020. What lies ahead? |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGRF, SIC, SAFM, TBIO; Shareholders are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / August 26, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:TGR Financial, Inc. (OTCQX:TGRF) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Foundation Inc. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds PFOH, TBIO, LDL, and SNR Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Pilgrim’s Pride and Icosavax See Activist ActionJBS Brazil offered to buy the rest of poultry-producer Pilgrim’s Pride. RA Capital disclosed a large position in biotech Icosavax. |
TBIO Price Returns
| 1-mo | 53.43% |
| 3-mo | 11.83% |
| 6-mo | 0.00% |
| 1-year | -74.11% |
| 3-year | -75.49% |
| 5-year | N/A |
| YTD | 57.50% |
| 2022 | -88.89% |
| 2021 | -41.40% |
| 2020 | 126.41% |
| 2019 | 8.53% |
| 2018 | N/A |
Continue Researching TBIO
Want to do more research on Translate Bio Inc's stock and its price? Try the links below:Translate Bio Inc (TBIO) Stock Price | Nasdaq
Translate Bio Inc (TBIO) Stock Quote, History and News - Yahoo Finance
Translate Bio Inc (TBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...